Junie

It sounds like you really got worked over. I hurts to read stories like yours. I have seen a lot of failed back surgeries.....spinal traumas also occur from accidents and even from injections. I won't let them stick another needle in my spine either, and I don't have your issues!

My current neuro is adamant about having no further spinal trauma for me....my current neuro didn't do any of the previous needle sticks. I have had 3 spinal anesthesias for C sections, 3 spinal nerve root blocks for herniated discs which are basically inoperable due to location and my condition, 1 lumbar puncture, oh and one high speed head on with a truck..gee I almost forgot that.

I do not do well with general anesthesia...hence the spinals.

It is tough enough when they do the surgery correctly, let alone when they make mistakes! It sounds like your experience was hideous.

Thanks for sharing your story, I hope people consider what you have endured prior to taking any actions. It is hard to predict the outcome of procedures. I hope you can find some comfort from something, in the future. It sounds like you have tough going right now.

This is the article I linked to:

....Medscape Alerts
Bisphosphonate Therapy Linked to Risk for Severe Musculoskeletal Pain


Yael Waknine
Information from Industry

January 8, 2008 — Temporary or permanent discontinuation of bisphosphonate therapy should be considered in patients who present with severe musculoskeletal pain, the US Food and Drug Administration (FDA) warned healthcare professionals yesterday. Overlooking bisphosphonate therapy as a causal factor may delay diagnosis, thereby prolonging pain and/or impairment and the use of analgesics. In contrast with the acute-phase response that sometimes accompanies initial exposure to bisphosphonate therapy, some patients experience severe and sometimes incapacitating bone, joint, and/or muscle pain that begins months or years later.

The incidence rate and risk factors for this reaction remain unknown, according to an alert sent from MedWatch, the FDA's safety information and adverse event reporting program. Moreover, discontinuation of therapy may not lead to complete relief — some patients have reported slow or incomplete resolution of symptoms.

Over the next 6 months, the FDA will be evaluating reports of severe musculoskeletal pain associated with bisphosphonate use. In the interim, patients reporting these symptoms should be monitored, and alternative causes for pain should be considered for those who do not experience a lessening or resolution of symptoms after bisphosphonate withdrawal.

Bisphosphonates are indicated for the prevention and treatment of osteoporosis and for treating hypercalcemia of malignancy and Paget's disease. They also are beneficial in patients with multiple myeloma and bone metastases from solid tumors.

Currently marketed oral bisphosphonates include risedronate sodium tablets (Actonel and Actonel + Ca, Proctor & Gamble Pharmaceuticals, Inc), alendronate sodium tablets (Fosamax and Fosamax + D, Merck & Company, Inc), ibandronate sodium tablets (Boniva, Roche), etidronate disodium tablets (Didronel, Proctor & Gamble), and tiludronate disodium tablets (Skelid, sanofi-aventis US, LLC).

Injectable bisphosphonates include pamidronate disodium injection (Aredia, Novartis Pharmaceuticals Corp) and zoledronic acid injection (Reclast and Zometa, Novartis)..........
Medscape Medical News 2008. .....

Billye